Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Zoladex (goserelin) is indicated for use in combination with flutamide for the management of locally confined carcinoma of the prostate and as palliative treatment of advanced carcinoma of the prostate.
• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• The provided study does not include any specific effectiveness outcomes for goserelin or other GnRH agonists/antagonists in the treatment of prostate cancer.
• Comparisons of effectiveness between goserelin and other drugs, such as degarelix, relugolix, or leuprolide, are not possible based on the study, as it lacks relevant data.
• The study does not provide any information regarding differences in effectiveness outcomes among various population types or subgroups.
• The pooled risk ratio for adverse cardiovascular events among GnRH antagonist recipients (including degarelix and relugolix) was 0.57 (95% CI: 0.39-0.81) compared to GnRH agonists (goserelin and leuprolide), indicating a lower risk associated with antagonists.
• The pooled risk ratio for cardiovascular death and all-cause mortality was 0.49 (95% CI: 0.25-0.96) and 0.48 (95% CI: 0.28-0.83) respectively, for GnRH antagonists, showing a reduced risk compared to GnRH agonists.
• There is no population types or subgroups information available in the reviewed studies.